Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

BACKGROUND: Vaccination with a recombinant modified vaccinia Ankara expressing antigen 85A from Mycobacterium tuberculosis, MVA85A, induces high levels of cellular immune responses in UK volunteers. We assessed the safety and immunogenicity of this new vaccine in West African volunteers. METHODS AND...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän:	Brookes, R, Hill, A, Owiafe, P, Ibanga, H, Jeffries, D, Donkor, SA, Fletcher, H, Hammond, A, Lienhardt, C, Adegbola, R, McShane, H
Materialtyp:	Journal article
Språk:	English
Publicerad:	Public Library of Science 2008

Liknande verk

Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.
av: Roger H Brookes, et al.
Publicerad: (2008-08-01)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa.
av: Roger H. Brookes, et al.
Publicerad: (2011-01-01)

Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.
av: Ibanga, H, et al.
Publicerad: (2006)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
av: Owiafe, P, et al.
Publicerad: (2012)

Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
av: Ota, M, et al.
Publicerad: (2011)

Immunogenicity of the Tuberculosis Vaccine MVA85A Is Reduced by Coadministration with EPI Vaccines in a Randomized Controlled Trial in Gambian Infants
av: Ota, M, et al.
Publicerad: (2011)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
av: Pathan, A, et al.
Publicerad: (2012)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
av: Pathan, A, et al.
Publicerad: (2012)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery
av: Meyer, J, et al.
Publicerad: (2013)

Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
av: Mcshane, H, et al.
Publicerad: (2005)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
av: Whelan, K, et al.
Publicerad: (2009)

Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery.
av: Meyer, J, et al.
Publicerad: (2013)

A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicity
av: Rowland, R, et al.
Publicerad: (2012)

The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.
av: Ota, M, et al.
Publicerad: (2007)

Comparison of the safety and immunogenicity of a candidate TB vaccine, MVA85A, given by the intramuscular or intradermal route in BCG-vaccinated adults
av: Harris, S, et al.
Publicerad: (2011)

Correction: Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa
Publicerad: (2011-01-01)

Evaluation of the safety and immunogenicity of a candidate tuberculosis vaccine, MVA85A, delivered by aerosol to the lungs of macaques.
av: White, A, et al.
Publicerad: (2013)

A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults
av: Minassian, A, et al.
Publicerad: (2011)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
av: Hawkridge, T, et al.
Publicerad: (2008)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection
av: Betts, G, et al.
Publicerad: (2012)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
av: Kathryn T. Whelan, et al.
Publicerad: (2011-01-01)

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.
av: Sander, C, et al.
Publicerad: (2009)

Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
av: Rowland, R, et al.
Publicerad: (2013)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses
av: Tameris, M, et al.
Publicerad: (2014)

Evaluating aerosol administration of a candidate TB vaccine MVA85A
av: Thomas, Z, et al.
Publicerad: (2014)

A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
av: Minhinnick, A, et al.
Publicerad: (2016)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
av: Odutola, A, et al.
Publicerad: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
av: Odutola, A, et al.
Publicerad: (2012)

Boosting BCG vaccination with MVA85A down-regulates the immunoregulatory cytokine TGF-beta1.
av: Fletcher, H, et al.
Publicerad: (2008)

The effect of current Schistosoma mansoni infection on the immunogenicity of a candidate TB vaccine, MVA85A, in BCG-vaccinated adolescents: An open-label trial
av: Wajja, A, et al.
Publicerad: (2017)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel Mycobacterium tuberculosis vaccine MVA85A.
av: Griffiths, K, et al.
Publicerad: (2011)

Th1/Th17 cell induction and corresponding reduction in ATP consumption following vaccination with the novel mycobacterium tuberculosis vaccine MVA85A
av: Griffiths, K, et al.
Publicerad: (2011)

Optimising immunogenicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection.
av: Gareth Betts, et al.
Publicerad: (2012-01-01)

Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate TB vaccine, MVA85A, alone and in combination
av: Harris, S, et al.
Publicerad: (2013)

Phase I trial evaluating the safety and immunogenicity of candidate TB vaccine MVA85A, delivered by aerosol to healthy M.tb-infected adults
av: Riste, M, et al.
Publicerad: (2021)

The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
av: Tameris, M, et al.
Publicerad: (2014)

Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial
av: Satti, I, et al.
Publicerad: (2014)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
av: Wilkie, M, et al.
Publicerad: (2019)

Two doses of candidate TB vaccine MVA85A in antiretroviral therapy (ART) naive subjects gives comparable immunogenicity to one dose in ART+ subjects
av: Dieye, T, et al.
Publicerad: (2013)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
av: Mcshane, H
Publicerad: (2008)